Liver Neoplasm
31
7
7
8
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.9%
4 terminated out of 31 trials
66.7%
-19.9% vs benchmark
10%
3 trials in Phase 3/4
25%
2 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (31)
Digitally Supported Prehabilitation Before Major Visceral Cancer Surgery
Prediction Model for MINS After Major Hepatobiliary Surgery
Y-90 Treatment Response Using Transarterial Radioembolization
GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy
Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease
Variability of Microwave Ablation Volume Based on Clinical, Radiological, Biological, and Tissue Factors
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases
SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA
Perioperative Myocardial and Renal Injury in Patients Undergoing Hepatic Resection
TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma
Proton Beam Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors
Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT)
Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation
Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma
Biliary or Digestive Protection by Room Air Interposition for Thermal Ablation of Central Hepatic Tumors
Feasibility of Ultrasound-based Navigation for Non-anatomical Liver Resections
Value of Functional Magnetic Resonance Imaging of Hepatocellular Carcinoma After Transarterial Chemoembolization or Transarterial Radioembolization